Pairs with the Cannibalization Decision Tree — a ready-to-use strategy tool. Included with a subscription, or $1.99.

In November 2014, Philip Morris did not launch IQOS to the world. It launched it to a single Japanese city. A heated-tobacco device that warms a stick instead of burning it went on sale in Nagoya, with a simultaneous pilot in Milan, and national Japanese rollout only the following year.4 This is not how a confident company behaves when it believes it has the future of nicotine in its hand. It is how a company behaves when it is testing exactly where, and only where, the rules will let it sell something new.

The official story is that the world's largest tobacco company decided to kill its own product. PMI says it is engineering its own decline - deliberately cannibalizing cigarettes with smoke-free alternatives. Smoke-free products reached roughly 39% of 2024 net revenue, with an estimated 38.6 million adults using them across 95 markets.1 By any normal reading, that is one of the most aggressive acts of self-cannibalization in corporate history. The trouble is that the cigarette business it is supposedly cannibalizing kept growing.

The business it claims to be killing is up 4%

Here is the number that breaks the narrative. In full-year 2024, while smoke-free products climbed to 39% of revenue, PMI's combustible net revenue grew 4.0% - and 5.9% organically. In the fourth quarter, combustibles grew 6.2% organically.6 Cigarette volumes are softening, yes, but the dollars are rising, pushed up by price. A company genuinely destroying its core product does not report its core product as a growth engine. The cannibalization framing makes PMI sound like it is sacrificing the present for the future. The results say it is being paid twice: a maturing cigarette business that still raises prices faster than it loses smokers, and a smoke-free business growing on top of it.

+4.0%
PMI's combustible cigarette net revenue growth in 2024 - the same year smoke-free products reached ~39% of the total. Revenue is growing - even as cigarette volumes soften, price more than compensates.6

So if it isn't cannibalization, what is it? The real mechanism is geographic, not generational. IQOS thrives where regulators permit heated tobacco - Japan most famously, where the device found a culture and a rulebook ready to receive it. In markets where IQOS cannot be sold, cigarette volumes and pricing stay robust: PMI's own Q4 2024 results attributed combustible revenue growth explicitly to "growing industry volumes in markets where smoke-free products are not allowed, including Turkey, India, Brazil and Vietnam."6 PMI isn't destroying its cigarette business so much as arbitraging the gap between markets that allow smoke-free products and markets that don't. Where the new product is legal and accepted, it migrates smokers. Where it isn't, the old product keeps printing. The company collects the spread.

The cannibalization storyWhat the numbers show
Cigarette businessBeing deliberately killedNet revenue up 4.0% (5.9% organic)
Smoke-free shareReplacing cigarettes~39% of revenue, growing alongside them
The driverA bet on public healthThe regulatory map of each market
What PMI is doingSacrificing the coreArbitraging the gap between markets
Two stories about the same company in 2024

ZYN was the future PMI bought, not the one it built

The other half of the smoke-free pivot is a small white pouch you tuck under your lip, and it is worth being precise about its parentage. ZYN was developed and owned by Swedish Match AB long before PMI was in the picture. PMI did not invent it; it acquired it, through a public cash offer for Swedish Match that opened at SEK 106 a share in May 2022, was raised to a best-and-final SEK 116, and closed on November 25, 2022 - valuing the target at roughly US$16 billion.3 This matters because the conventional telling treats ZYN as proof of PMI's innovation engine. It is better read as proof of PMI's checkbook. When the company could not build the future fast enough, it bought a company that already had.

And the purchase is performing. In Q4 2024, U.S. ZYN shipments hit nearly 165 million cans, up almost 42% year-over-year, while full-year oral smoke-free volume rose nearly 28%.2 The trajectory steepened into 2025: Q1 U.S. ZYN shipments reached 202 million cans, a 53% jump year-over-year.10 PMI's full-year 2025 guidance called for 780 to 820 million cans - representing growth of 34% to 41% versus 2024.7 Those are the curves of a company that found, rather than created, its second act - and timed the acquisition to ride it.

But Japan's cigarette sales really did fall off a cliff

The strongest objection to all this is Japan, and it is a fair one. After IQOS arrived, the country's per-capita cigarette decline went from a gentle slide to a collapse: the annual decline rate accelerated from −1.5% in 2011–2015 to −10.5% in 2015–2018, the very window of rapid heated-tobacco growth, with cigarette sales down 52.7% from 2011 to 2023.5 That looks like clean substitution - smokers switching, cigarettes dying, exactly the story PMI tells. If self-cannibalization is a myth, Japan is the inconvenient counter-evidence.

Except the cleanest part of the story is the part the evidence can't support. A 2026 scoping review in Nicotine & Tobacco Research notes that those sales analyses 'do not distinguish the role of cigarette prices, prevalence versus quantity purchased, or dual cigarette-HTP versus exclusive cigarette use.'5 In plain terms: we don't know how much of the cigarette decline was IQOS converting smokers, how much was tax-driven pricing, and how many people simply use both. Independent work has found considerable dual-use - multiple studies document IQOS users who continue smoking cigarettes concurrently, with some researchers characterizing HTPs as complements to cigarettes rather than substitutes.9 A leaked 2019 Philip Morris Japan strategy document, analyzed by the watchdog STOP, showed the company planning to lobby for IQOS use in smoke-free spaces and favorable taxation while sustaining its cigarette market position - the two products as a portfolio, not a relay race.8 Japan didn't prove cannibalization. It proved a regulatory environment that let one product grow without forcing the other to die.

...do not distinguish the role of cigarette prices, prevalence versus quantity purchased, or dual cigarette-HTP versus exclusive cigarette use.5
Nicotine & Tobacco Research2026 scoping review of cigarette and heated-tobacco trends in Japan
Cannibalization is a story; arbitrage is a strategy

When an incumbent says it is bravely killing its own cash cow, check whether the cash cow is actually dying. PMI's combustibles grew 4% the year smoke-free hit 39% of revenue - which means the new business is being added, not substituted, and the company is harvesting both wherever the rules allow. The lesson for any incumbent facing disruption: you don't have to choose between the old product and the new one if you can segment by where each is permitted to win. The risk is believing your own press release. A regulatory gap is a temporary asset, not a moat - rules in one market can become rules in all of them, and the arbitrage closes the moment the laggard markets catch up.

PMI deserves real credit: the smoke-free pivot is financially validated, accretive to gross margin, and not a vanity project. But the word 'cannibalization' flatters it. A cannibal eats its own to survive. PMI is doing something colder and smarter - selling the future where the future is legal, and the past everywhere else, and counting both. The genius was never killing the cigarette. It was discovering that in a world of mismatched rulebooks, you never have to.

Take it with you — The Cannibalization Choice
Decision Tree

Cannibalization Decision Tree

A decision tree for the moment the new thing threatens the cash cow: is the disruption real, will someone else do it if you don't, and can you afford to bleed your own margin to own the future? Blank to run on your own line; filled as the worked example tracing how the story's incumbent chose to cannibalize — or flinched and got cannibalized.

Blank template

Included with any subscription, or unlock this tool for $1.99. Get it → · See plans →

Sources

Where this comes from — the filings, records, and reporting behind it.

  1. 1
    Primary · Company recordDocumented
    PMI's smoke-free business accounted for approximately 39% of total full-year 2024 net revenues; as of December 31, 2024, PMI estimates 38.6 million adults use PMI smoke-free products available in 95 markets.
  2. 2
    Primary · Company recordDocumented
    In Q4 2024, ZYN U.S. shipments reached nearly 165 million cans, growth of nearly 42% year-over-year; full-year 2024 oral SFP shipment volume increased by nearly 28% in cans.
  3. 3
    Primary · SEC filingDocumented
    PMI's subsidiary Philip Morris Holland Holdings B.V. announced the public cash offer for Swedish Match at SEK 106/share on May 11, 2022; the final best-and-final price was raised to SEK 116/share; the acquisition closed November 25, 2022; assuming 100% ownership the deal valued Swedish Match at approximately US$16 billion.
  4. 4
    Primary · Company recordDocumented
    IQOS was first introduced in Nagoya, Japan, in November 2014 as a city-wide pilot, with national rollout beginning in 2015; Milan, Italy was a simultaneous second pilot city.
  5. 5
    Primary · AcademicDocumented
    In Japan, the annual percentage decline in per capita cigarette sales accelerated from −1.5% (2011–2015) to −10.5% (2015–2018) during the period of rapid HTP growth; cigarette sales declined 52.7% from 2011 to 2023. However, sales analyses do not distinguish the role of cigarette prices, prevalence versus quantity purchased, or dual-use versus exclusive cigarette use.
  6. 6
    Primary · Company recordDocumented
    PMI's combustibles full-year 2024 net revenues grew 4.0% (5.9% organically) driven by strong pricing; Q4 2024 combustible net revenues grew 6.0% (6.2% organically). Cigarette volumes are softening but revenue is growing via price.
  7. 7
    Primary · Company recordDocumented
    PMI's 2025 guidance (issued Feb 2026) projects U.S. ZYN shipment volumes of 780–820 million cans, representing growth of 34–41% versus 2024's ~581 million cans; Q1 2025 U.S. ZYN shipments reached 202 million cans, a 53% year-over-year increase.
  8. 8
    PublishedAttributed to source
    A leaked 2019 internal Philip Morris Japan business strategy document (analyzed by tobacco-industry watchdog STOP) showed PMJ planned multi-pronged influence of policymakers, medical professionals, and consumers to grow IQOS acceptance — including lobbying for IQOS use in smoke-free spaces and favorable taxation — while simultaneously sustaining PMJ's cigarette market position, undermining the clean 'cannibalization for public health' narrative.
  9. 9
    PublishedAttributed to source
    Multiple independent studies have found considerable dual and poly use of IQOS and cigarettes concurrently, with some studies suggesting HTPs serve as complements rather than substitutes for cigarettes.
  10. 10
    Primary · Company recordDocumented
    PMI Q1 2025 U.S. ZYN shipments exceeded 200 million cans, representing 53% growth versus Q1 2024, exceeding initial expectations as production capacity increased ahead of schedule.